Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rollover Study to Continue IMSA101 Treatments in Patients With Advanced Treatment-Refractory Malignancies Previously Enrolled in the Phase I/IIA Safety and Efficacy Study of IMSA101

NCT06026254 is registered in ClinicalTrials.gov with ImmuneSensor Therapeutics Inc. as lead sponsor.

NCT NCT06026254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06026254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rollover Study to Continue IMSA101 Treatments in Patients With Advanced Treatment-Refractory Malignancies Previously Enrolled in the Phase I/IIA Safety and Efficacy Study of IMSA101
Lead sponsor
ImmuneSensor Therapeutics Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 15, 2023
Completion date
September 30, 2025
Enrollment
2 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult